Prescription Drug Monitoring Program: New Hampshire State Profile (2021)

• NCJ Number: 303729
• Date Published: 2021
• Length: 13 pages
• Grant Number(s): 2017–AR–BX–K003
• Agencies: BJA-Sponsored
• Publication Type: Report (Grant Sponsored)

Annotation

The Prescription Drug Monitoring Program Training and Technical Assistance Center (PDMP TTAC) reports 2020 data and 2021 features of the New Hampshire state Prescription Drug Monitoring Program (PDMP).

Abstract

The name of New Hampshire’s PDMP is  ”New Hampshire.” It is administered by the New Hampshire Board of Pharmacy. The email address is provided, along with the URLs of the PDMP website and related websites for enrollment, query, and data upload. Contact information is provided for the Executive Director and Administrative Assistant. For 2020, the state population was 1,379,089, and there were 10,267 DEA-registered prescribers and 263 DEA-registered dispensers. A total of 20 PDMP available reports are listed. Sources of funding for the PDMP are the state general fund, licensing fees, and a CDC grant. The 2021 budget amount is not provided. Two staff members perform operational tasks, and one staff member conducts analytical/epidemiological work. Key dates for the establishment and development of the PDMP are provided. Ten miscellaneous capabilities and policies of the PDMP are listed. The data-retention policy includes the retention of de-identified data. No information is provided on the availability of or requirements for training in the features and use of the PDMP. Requirements for PDMP accounts are provided. Law enforcement agency use of the PDMP requires a subpoena, court order/approval, or a search warrant. Minimum and optional data elements needed for a query are reported. Enrollment in the PDMP is required for prescribers and dispensers. Prescribers are required to use the PDMP, and there is a compliance process for use mandates.  Veterinarians have access to an animal owner’s prescription history. The drugs monitored by the PDMP are listed in Schedules II-IV, naloxone/narcan administrations, fatal and non-fatal drug overdoses, and pharmaceutical manufacturers/distributors sales. Information is provided on technological capabilities, types of reports, and those authorized to receive them.